We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-9 of 9

Overview of patent-statutory subject matter in biotechnology

  • CCPIT Patent & Trademark Law Office
  • -
  • China, European Union, Japan, USA
  • -
  • April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound

The Patent Reexamination Board makes a clear explanation about whether the invention relating to embryonic stem cells is contrary to the social morality or not

  • Wan Hui Da Intellectual Property Agency
  • -
  • China
  • -
  • March 29 2013

Reexamination Board (PRB) on this case provides the guidance for the judgment on whether the invention relating to embryonic stem cells is contrary

Vitamin-C verdict may spell trouble ahead for multinational Chinese companies

  • Allen & Overy LLP
  • -
  • China
  • -
  • March 15 2013

On Thursday, March 14, a federal jury in New York found Chinese vitamin-C manufacturer Hebei Welcome Pharmaceutical Co. and its parent, North China

Global Pricing Newsletter: volume two

  • Sidley Austin LLP
  • -
  • China, Global, United Kingdom, USA
  • -
  • February 27 2013

Pharmaceutical and biologic manufacturers operate in an increasingly global economy where legal developments in one market may have cascading impacts

FCPA anti-corruption developments: 2012 end of summer round-up

  • Morrison & Foerster LLP
  • -
  • China, France, Global, Haiti, India, Mexico, United Kingdom, USA
  • -
  • October 10 2012

While the temperatures rose this summer, the number of Foreign Corrupt Practices Act enforcement actions seems to have cooled off for the first time in the last five years

Antitrust, competition and economic regulation client quarterly newsletter

  • Hogan Lovells
  • -
  • China, European Union, Greece, USA
  • -
  • January 24 2012

A public company CEO recently consented to a federal district court order requiring him to pay a $500,000 civil penalty for violating the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”

Life sciences health industry China briefing - November 2011

  • Reed Smith LLP
  • -
  • China
  • -
  • December 6 2011

The Beijing Health Bureau announced November 9 that the hospital grading appraisal will be initiated in 2012

The death penalty for perpetrators of food safety violations in China

  • Norton Rose LLP
  • -
  • China
  • -
  • June 6 2011

In the wake of continual food safety crises in China, the Supreme People's Court (Court) has called for courts to impose the death sentence for people convicted of food safety violations where those violations have resulted in death(s

China issues judicial interpretations on the application of law in criminal prosecutions involving the manufacturing or sale of counterfeit or inferior drugs

  • Hogan Lovells
  • -
  • China
  • -
  • August 31 2009

On May 27, 2009, the Supreme People’s Court and the Supreme People’s Procuratorate of China issued a set of judicial interpretations to govern certain issues concerning the specific application of law in trying criminal cases involving the production or sale of counterfeit or inferior drugs (the Judicial Interpretations

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy